EGFR and non-small cell lung carcinoma: Moreover, multiple clinical trials reported nearly doubled median progression-free survival times in NSCLC patients with activating mutations in EGFR receiving osimertinib compared to patients receiving erlotinib or gefitinib, resulting in the Food and Drug Administration’s (FDA) and European Medicine Agency’s (EMA) approval of osimertinib as a first-line treatment in 2018 [10,11,12,13,14,15].